Lombard Medical Company Description
Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally.
The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees.
Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement.
Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals.
The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.
| Country | Cayman Islands |
| Founded | 2000 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 113 |
| CEO | Kurt Lemvigh |
Contact Details
Address: 4 Trident Park Didcot, OX11 7HJ United Kingdom | |
| Phone | 44 12 3575 0800 |
| Website | lombardmedical.com |
Stock Details
| Ticker Symbol | EVARF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | KYG555981094 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kurt B. Lemvigh | Chief Executive Officer |
| Dr. Peter Phillips | Chief Technology Officer |
| Andrew Debbage | Vice President of Operations |
| Jonathan Hornsby | Vice President of Sales and Marketing |
| Kate Forster | Vice President of Human Resources |
| Paul Hardwick | Vice President of Sales |